IMPORTANCE High-deductible health plans (HDHPs) have expanded under the Affordable Care Act and are expected to play a major role in the future of US health policy. The effects of modern HDHPs on chronically ill patients and adverse outcomes are unknown.
1
Diabetes is a major cause of morbidity and premature death in the United States. 2, 3 High cost-sharing might especially affect chronically ill patients who require frequent and expensive services. However, the effects of HDHPs on outpatient care patterns and adverse outcomes among chronically ill patients are unknown.
We hypothesized that some outpatient care, including preventive tests that are inexpensive even under HDHPs, would remain stable among HDHP members with diabetes. We further hypothesized that relatively expensive care, such as specialist visits and outpatient visits for acute complications (typically paid out of pocket until the deductible is met), would decline or be delayed, increasing the frequency and severity of emergency department (ED) visits for acute complications.
Methods

Study Population
We drew our study population from commercially insured members in the Optum database (Eden Prairie, Minnesota) enrolled between January 1, 2003, and December 31, 2012. Data comprised enrollment tables and all medical, pharmacy, and hospitalization claims from members of a large national health plan. We included members in the study based on their employers' health insurance offerings. We defined employers with low-and high-deductible coverage as those offering exclusively annual deductibles of $500 or less or $1000 or more, respectively (eAppendix in the Supplement). To determine employers' annual deductibles, we used a benefits variable that was available for most smaller employers (approximately ≤100 employees, representing 57.7% of account years) that included information such as in-network and out-of-network deductible, copayment, and coinsurance amounts. For larger employers (42.4% of account years), we imputed deductible levels using out-of-pocket spending among employees who used health services with an algorithm that had 96.2% sensitivity and 97.0% specificity (eTable 1 in the Supplement). The research protocol, with waiver of informed consent, was approved by the Harvard Pilgrim Health Care institutional review board.
Both low-and high-deductible plans often cover a single annual preventive primary care visit and disease monitoring, such as hemoglobin A 1c testing, at low or no out-of-pocket cost. 1 In contrast, HDHP members on average must pay substantially higher amounts than low-deductible members for specialist, acute care, and ED visits.
Our study groups were drawn from individuals whose employers mandated an HDHP switch (HDHP group) or mandated continuation in low-deductible plans (control group), minimizing self-selection. We required HDHP group members to have 12 baseline months in a low-deductible plan followed by 24 months in an HDHP after the employermandated HDHP switch (36 continuous enrollment months per member). We defined the beginning of the month of the lowto high-deductible transition as the index date. We identified all potential control group members whose employers offered only low-deductible plans over at least a 3-year period (n = 1 674 527).
To further minimize potential selection effects, especially at the employer level, we used a 2-level (employer and member level) propensity score-matching approach 4, 5 (eAppendix in the Supplement) and estimated propensity scores predicting the likelihood of a mandated HDHP switch. After matching at the employer level on multiple characteristics (eAppendix in the Supplement), we identified patients with diabetes aged 12 to 64 years using a standard claims-based algorithm (eTable 2 in the Supplement) (12 854 HDHP members and 69 749 control pool members) ( Table 1) . We included patients who first met the diabetes diagnosis algorithm criteria at least 6 months before the index date and who had diabetes diagnoses or medication use between 6 months before and 6 months after the beginning of the baseline year.
Within quartiles of the employer propensity score, we matched HDHP members with diabetes at the patient level 1:1 to controls with diabetes based on age, adjusted clinical group (ACG) morbidity score,
Measures Utilization and Disease Monitoring Measures
We used standard algorithms for detecting outpatient visits with Current Procedural Terminology evaluation and management codes and a clinician type variable to classify visits as primary care or specialist. We then applied a taxonomy developed by Fenton and colleagues 13 (eAppendix in the Supplement) to characterize each office visit as high priority or low a Percentages reflect the value after the small number of members with missing information were excluded from the denominator.
b Only 0.1% of HDHP members and 0.2% of control group members (<1.0%) had missing race/ethnicity information; 0.1% of HDHP members and 0.2% of control group members (<1.0%) had missing educational level and poverty
Health Outcome Measures
To assess whether HDHPs were associated with changes in time-sensitive care, 2 of us (J.F.W. a n d E.M.E.) used a systematic approach to develop a measure of outpatient and ED visits that could indicate a preventable acute diabetes complication, hereinafter termed complication visit (eAppendix and eTable 4 in the Supplement). Acute diabetes complications were defined as symptoms or conditions (when coded by clinicians as the primary diagnosis) that could be associated with delaying recommended or urgent diabetes-related outpatient or ED care (including prescription drug use) for up to 4 months and that require timely care by medical professionals (eFigure 1 in the Supplement). This measure was validated in our population (eTables 5 and 6 in the Supplement) by determining that outpatient and ED visits with these complication diagnoses were associated with odds ratios of 4.10 (95% CI, 3.98-4.23) for outpatient visits and 3.02 (95% CI, 2.96-3.08) for ED visits of subsequent hospitalization compared with other types of outpatient or ED visits. The 5 most common categories of outpatient complication visits at baseline, accounting for 82.0% of such visits, were cellulitis, urinary tract infection, angina and ischemic heart disease, acute cerebrovascular disease, and pneumonia. The 5 most common categories of ED complication visits at baseline, accounting for 62.0% of such visits, were cellulitis, urinary tract infection, hypoglycemia or hyperglycemia and their major acute complications, angina and ischemic heart disease, and pneumonia. All health care expenditures during the 7 days after an acute complication visit to the ED were summed as a health outcome measure to assess the intensity of and need for diagnostic and therapeutic services. That is, we included this as a proxy to indicate level of "sickness" at presentation to the ED. Health care expenditures were from a data vendor-provided variable that was standardized across geography and time and represents combined health plan and patient payments.
Covariates
We applied the Johns Hopkins ACG System comorbidity score (version 10.0.1) algorithm, a validated measure that predicts mortality, 6, 15 to members' baseline year to estimate comorbidity and defined high and low morbidity as ACG scores of 3.0 or higher and lower than 2.0, respectively. Using 2000 US Census block group data and validated methods, 16,17 members were considered high and low income based on living in neighborhoods with below-poverty levels of less than 5% and 10% or higher, respectively, and a similar approach to categorizing educational levels was used. [16] [17] [18] [19] [20] [21] Members were classified as white, black, Hispanic, Asian, or other based on a combination of geocoding and surname analysis (eAppendix in the Supplement). 22, 23 Other covariates included age category (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) (40) (41) (42) (43) (44) (45) , and 46-64 years), sex, and US region (West, Midwest, South, and Northeast).
Statistical Analysis
Baseline characteristics of our study groups were compared using χ 2 tests; unpaired, 2-tailed t tests; and nonparametric tests. Continuous measures are reported as mean (SD), and categorical variables are reported as count (percentage). 24 In all statistical models estimating HDHP effects, we removed from analyses the month before and after the index date to reduce bias due to anticipatory increases in utilization before the HDHP switch (and consequent reductions in the month after the switch). For the high-priority primary care and specialist visit outcomes, we first fit interrupted-time-series models 25 to both visually display monthly trends and confirm that the study groups did not have differential baseline trends-a key assumption of difference-in-differences analysis. We then used difference-in-differences analysis to examine changes in annual high-priority outpatient visits and disease monitoring measures. Generalized estimating equation 26,27 models with a negative binomial distribution for outpatient visits and a binary distribution for disease monitoring measures were applied, controlling for age, sex, race/ethnicity, educational level, poverty level, US region, ACG score, employer size, and index date.
To examine time to first outpatient and ED visits for acute complications, we used separate Cox proportional hazards regression models for the baseline and follow-up periods, adjusting for the same covariates as listed above. To analyze annual changes in complication visits and subsequent 7-day total expenditures, aggregate-level segmented regression was applied to cumulative rates that had been adjusted for the above covariates (eAppendix in the Supplement).
Using the same methods and outcomes as described above, subgroup analyses stratified by low and high income and morbidity were performed and HSA-eligible members and their matched pairs were examined. We also assessed several other subgroups of interest, including those defined by different income cutoff levels (residing in neighborhoods with <10%, >5%, and >20% of households below the federal poverty level) and residents of predominantly white and nonwhite race neighborhoods. As a sensitivity analysis, we restricted the sample to members aged 18 to 64 years, rematched, and then analyzed all primary outcomes. Data analysis was performed from February 23, 2015, to September 11, 2016 . Statistical analysis was performed using SAS, version 9.4 (SAS Institute Inc) and Stata, version 12.1 (StataCorp).
Utilization and Disease Monitoring Measures
Interrupted-time-series analyses demonstrated no statistically significant baseline trend differences between the HDHP and control groups in high-priority outpatient visits for all subgroups (implying validity of difference-in-differences estimates; eTable 9 in the Supplement) except primary care visits among low-morbidity members. In adjusted difference-indifferences analyses, relative changes in high-priority primary care visits occurred only in the low-morbidity (−5.1%; 95% CI, −8.6% to −1.6%), high-income (−5.7%; 95% CI, −10.5% to −0.9%), and low-income (−5.2%; 95% CI, −9.8% to −0.7%) subgroups from baseline to follow-up year 2 ( Table 2 ; eFigure 2 in the Supplement).
High-priority specialist visits declined in the overall HDHP cohort by 5.5% (95% CI, −9.6% to −1.5%) in follow-up year 1 and 7.1% (95% CI, −11.5% to −2.7%) in follow-up year 2 vs baseline. Among the low-and high-morbidity HDHP subgroups compared with controls, year 2 vs baseline changes in highpriority specialist visits were −7.9% (95% CI, −14.4% to −1.4%) for the low-morbidity subgroup and −12.2% (95% CI, −17.9% to −6.5%) for the high-morbidity subgroup. Corresponding changes among high-and low-income HDHP members were −10.7% (95% CI, −17.1% to −4.3%) and −7.6% (95% CI, −15.9% to 0.7%). c Adjusted clinical group score of 3 or higher.
d Living in neighborhoods with below-poverty levels of less than 5%.
e Living in neighborhoods with below-poverty levels of 10% or greater.
f Health savings accounts allow pre-tax contributions from employers or members; funds can be used to pay for qualified medical expenses.
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Health Outcome Measures
The overall HDHP diabetes cohort experienced a follow-up period delay in the time to first outpatient complication visit 
Discussion
In this study, HDHP members with diabetes experienced minimal changes in high-priority outpatient visits and disease monitoring measures, but they delayed presenting for first outpatient complication visits and experienced 5.6% to 8.0% increases in ED complication measures. Low-income and highmorbidity HDHP members also experienced delays in presenting for outpatient complication visits after the HDHP switch, and these groups, as well as HSA HDHP members, experienced moderate to large increases in ED acute complication visits or expenditures.
The results are generally consistent with our hypotheses. Reductions in specialist visits were smaller than expected, but the decline in this rate might have been tempered by an increased need for specialist care because of increased severity of diabetes complications. Although we cannot directly determine whether delayed outpatient complication visits caused increased morbidity among vulnerable HDHP members, the large increases in ED complication episode costs that were detected seem suggestive. Despite some uncertainty about causal mechanisms and morbidity impact, increased acute diabetes complications and associated expenditures are almost certainly unintended consequences that all stakeholders wish to avoid. Another potential implication of this study is that adverse HDHP effects in diabetes would have gone undetected if assessed using traditional Healthcare Effectiveness Data and Information Set disease monitoring metrics, suggesting that health systems could benefit from adopting acute preventable diabetes complication measures, such as the one we created and validated.
Reasons for the acute complication findings may be clarified by considering the effects in the key patient subgroups. It is likely that high-morbidity, low-income, and HSA-eligible patients with diabetes (who experienced the largest costsharing increases) had significantly greater concerns about HDHP-related out-of-pocket spending than did their less vulnerable HDHP counterparts. These patients might therefore attempt to minimize health expenditures by forgoing expensive scheduled and acute visits or by shifting care to less expensive but potentially less appropriate settings. Such effects might lead to more severe disease by the time of presentation for acute complications. Adverse outcomes among HSA HDHP members might imply that HSA funding levels were low, that patients were unaware of this resource, or that they engaged in inappropriate attempts to preserve HSA funds. These findings among subgroups suggest that a bifurcation of outpatient care could be occurring among HDHP members with diabetes, with less vulnerable patients largely unaffected but more vulnerable patients facing access limitations that ultimately increase acute care utilization. Future studies could directly assess the causal association between care delays and acute complication visits and determine whether other factors, such as medication nonadherence, play any role.
To our knowledge, no previous research has examined outpatient visits or complications among HDHP patients with diabetes. The landmark RAND Health Insurance Experiment from 40 years ago predicted that the "poor and sick" would have increased long-term mortality under high-level cost sharing due to worsened hypertension control. 11 Our study, which occurs in a different health care era and was able to enroll a far larger sample of chronically ill patients, is, to our knowledge, the first to examine acute complication measures among chronically ill HDHP members. The study adds the key finding that concerning utilization patterns increase soon after an HDHP switch among similarly vulnerable populations. Other chronically ill HDHP patients who require time-sensitive care, such as those with coronary heart disease, heart failure, or cancer, might be at risk, but further research is warranted. Two previous studies found minimal or no changes in several diabetes disease monitoring metrics 28, 29 ; similarly, we detected no changes in such measures, likely related to low out-of-pocket costs (eTable 8 in the Supplement) and perhaps the perceived nondiscretionary nature of these tests (eg, retinal eye examinations). These findings should be reassuring to primary care physicians both because they might presage unchanged long-term disease control under HDHPs and because the rates of such tests are increasingly being used to measure clinician performance. Our disease monitoring results also confirm a growing body of literature demonstrating that excluding high-value services, such as secondary preventive tests, from cost-sharing under HDHPs might help to preserve their use.
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HDHP Control
Unadjusted plots with adjusted hazard ratios (aHRs) for low-morbidity (A) and high-morbidity (B) members. Total expenditures during acute complication episodes is a proxy indicating utilization in the 7 days after an emergency department (ED) visit for preventable acute diabetes complications. Switch to a high-deductible health plan (HDHP) was considered the index date.
a Adjusted Clinical Group score lower than 2.0 (low morbidity). 
Unadjusted plots with adjusted hazard ratios (aHRs) for high-income (A) and low-income (B) members. Total expenditures during acute complication episodes is a proxy indicating utilization in the 7 days after an emergency department (ED) visit for preventable acute diabetes complications. Switch to a high-deductible health plan (HDHP) was considered the index date.
a Living in neighborhoods with below-poverty levels of less than 5%.
b Living in neighborhoods with below-poverty levels of 10% or greater.
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Limitations This study has several potential limitations. We did not have exact benefit coverage details for large employers, but we used a highly sensitive and specific algorithm for detecting their deductible levels. Furthermore, analyses of actual out-ofpocket expenditures showed that, at the population level, the HDHP group experienced increased out-of-pocket medical expenditures of approximately 50%, indicating the validity of our plan type classification. The measure of acute complication visits is novel, but we created the measure rigorously and validated it extensively, as described above and in the eAppendix in the Supplement. Furthermore, the top 5 diagnosis clusters (eg, cellulitis, urinary tract infection, hypoglycemia or hyperglycemia and their major acute complications, angina and ischemic heart disease, and pneumonia) have face validity, and analyses of this subset revealed similar patterns (eTable 18 in the Supplement). Nevertheless, measurement error is still possible given the lack of consensus regarding which diagnoses are considered "acute preventable diabetes complications" and the imprecision of International Classification of Diseases, Ninth
Revision diagnoses. We did not have information about HSA contributions, which could permit determining whether such funds modify the adverse outcomes that were detected. We also did not report changes in laboratory values (because of a high degree of missing values) or medication use. We did not have access to health insurance premiums and therefore could not estimate the total member expenditures (premiums plus out of pocket). Finally, this study is not representative of people with nonemployer-sponsored insurance, very low socioeconomic status, very high deductibles, or those whose first exposure to insurance is under HDHPs.
Conclusions
This study found that patients with diabetes experienced minimal changes in outpatient visits and disease monitoring after an HDHP switch, but low-income, high-morbidity, and HSA HDHP subgroups experienced major increases in ED visits or expenditures for preventable acute diabetes complications. These subgroups might be especially at risk in the increasingly HDHP-centric private US health system, and our results support a strategy of minimizing the enrollment of vulner- Role of the Funder/Sponsor: The funding organizations had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. enrolled in plans with a deductible are required to pay the full cost of most medical care until the plan deductible is met. Increases in health plan deductibles raise concerns that the proportion of household income dedicated to medical care will grow. In 2014, 23% of adults were underinsured (defined as outof-pocket costs that were high relative to income) compared with 13% in 2005. 3 Another concern is that larger plan deductibles will cause consumers to forgo essential, high-value medical care. Ideally deductibles would lead to a reduction in the use of only low-value care. To accomplish this goal, consumers must be able to distinguish between high-value and low-value clinical services, which is difficult. Thus, increased cost-sharing contributes to avoidance of both low-and high-value care. The study by Wharam and colleagues 4 in this issue of JAMA Internal
Medicine adds to a large and growing body of evidence reporting that while consumer cost-sharing may not have large deleterious health effects on the general population, low income and very sick populations are particularly vulnerable to cost-related nonadherence. The authors found that persons with diabetes decrease the use of evidence-based interventions in response to increased deductibles, which likely results in worse health outcomes. 4 Vulnerable groups may not have the savings available to pay for needed care, potentially affecting the ability to purchase other essential services such as food or housing. Despite the limitations associated with current costsharing strategies, out-of-pocket payments may be helpful in establishing a consumer-centric system and reducing the cost of care by better engaging patients in their health care decisionmaking. Yet, commonly used instruments, such as deductibles, are blunt and impose the same financial barriers to highand low-value clinical services. eAppendix.
I. eMethods
A. Study Group Construction and Deductible Imputation Algorithm
To determine employer deductible levels, we used a benefits type variable that we had for most smaller employers (with approximately 100 or fewer employees). For larger employers, we took advantage of the fact that health insurance claims data are the most accurate source for assessing out-of-pocket obligations among patients who utilize health services. Our claims data contained an in-network/out-of-network deductible payment field. For patients who use expensive or frequent services, the sum of their yearly deductible payments add up to clearly identifiable exact amounts such as $500.00, $1000.00, $2000.00, etc. When even several members have these same amounts, it provides strong evidence that the employer offered such an annual deductible level. It is also possible to detect employers that offer choices of deductible levels when multiple employees have deductibles at two or more levels, such as 20 employees with an annual amount of $1000.00 and 12 employees with $500.00. For employers with at least 10 workers, we therefore summed each employee's in-network deductible payments and number of claims over the enrollment year and assessed other key characteristics such as percentage with Health Savings Accounts. On a randomly selected half of the employer data set that contained our calculated employer characteristics (such as the percentage of patients with deductible levels between $1000-$2500) as well as actual deductible amounts, we used a logistic model that predicted the 3-level outcome of deductible <=$500/$500-$999/>$1000 based on multiple aggregate employer characteristics such as the first and second most common whole number deductible value, the percentage with Health Savings Accounts or Health Reimbursement Arrangements, the median deductible payment, the percentage of employees using services, the employer size, the percentage of employees with summed annual deductible amounts (from claims data) between $100 to ≤$500/ >$500 to <$1000/ ≥$1000 to ≤$2500/ >$2500, etc. This predictive model output the probability that employers had deductibles in the three categories (summing to 1) and we assigned the employer to the level that had the highest probability. If we detected employers that had 10 or more employees with whole number deductible levels both above and below $500 (e.g. $250.00 and $1500.00), we assigned the employers' category as "choice." If 100% of employees had Health Savings Accounts, we also overwrote any previous assignment to classify the employer as a high-deductible employer. We tested the predictive model on the other half of the sample for which we had actual deductible levels (eTable 1). At employers with 75-100 enrollees, we found sensitivity and a specificity of over 96%. The sensitivity and specificity would be expected to be even higher at employers with more than 100 enrollees (because more claims data would be available to provide evidence of deductible levels), but we were unable to test this because the dataset for which we had actual deductibles included employers with generally 100 or fewer enrollees.
Rationale for low-and high-deductible cutoff values: when health savings account-eligible HDHPs came to market in 2006, the Internal Revenue Service set the minimum deductible level for qualifying HDHPs at $1050 (which could be adjusted upward for inflation annually). The range of this minimum deductible during our study period was $1050-$1200. For these reasons, we defined HDHPs as annual individual deductibles of at least $1000 (otherwise health savings account plans would be excluded). In addition, choosing this cutoff (as opposed to e.g. $2000) also improves the sensitivity and specificity of the imputation because this is common deductible level and more enrollees per employer meet this threshold. This cutoff is also a "real-world" deductible minimum that allows the most generalizable results. We did not create a separate imputation algorithm for deductible levels of e.g. >=$2000 due to concerns that a less sensitive and specific algorithm would lead to biased effect estimates and a smaller HDHP sample size. It is important to note that $1000 was the minimum annual deductible level and not the mean deductible level. We cannot calculate the mean deductible level of the HDHP group directly but would expect it to be in the range of approximately $1500 to $2000.
We defined traditional plans as having deductible levels of ≤$500 after determining that a threshold of ≤$250 would lead to an inadequate sample size for the control group. Again, the mean deductible level of the control group members would be lower than $500.
After assigning deductible levels at the employer plan year level, we began with 1,830,665 employer plan years. We excluded 201,230 plan years (11%) that included deductible levels other than only low or only high. Among the remaining 1,629,435 plan years, we excluded 191,519 (12%) that did not have 2 years of continuous enrollment. Finally, from the remaining 1,437,916 employer plan years, we excluded 549,638 (38%) that were not transitions of low deductible to low deductible or low deductible to high deductible. Most of these exclusions were due to employers having high deductibles at their initial appearance in our dataset and remaining in high deductible plans.
Our HDHP group therefore comprised the enrollment years of employers that had a year-on-year transition from low-to high-deductible coverage (from $500 or less to $1000 or more). Some employers had multiple eligible index dates (e.g., multiple low-to-low deductible years or both low-to-low and low-to-high deductible years). In these cases, we randomly assigned employers to the HDHP or control pool then randomly selected one of their index dates (and their corresponding before-after enrollment years).
We identified patients with diabetes age 12 to 64 as defined by detection of 1 inpatient or 2 outpatient diagnosis codes for diabetes (eTable 2), or the dispensing of insulin or at least one oral hypoglycemic medication other than metformin alone, between 6 months before to 6 months after the beginning of members' baseline period.
B. Propensity Score Matching Approach
Propensity score matching assists in generating a control group with a similar likelihood of being exposed to a given "intervention" (in this case, shifting to HDHP coverage) based on measured characteristics when individuals have not been randomly allocated into study groups. [1] [2] [3] [4] To perform propensity score matching, we first included all employers with at least two years of enrollment. After classifying every employer's index date as before 2008 versus 2008 and later, we used an employer-level model to generate annual employer propensity score quartiles. This logistic model predicted the likelihood of an employer joining a HDHP in a given calendar period (before 2008 versus 2008 and after) based on calendar index date, employer size (<50, 50-99, 100-249, 250-499, 500+); percentage of women; members in income strata, education strata, age strata, race strata, and region strata; employer baseline cost level and trend; average employer Adjusted Clinical Groups (ACG) score; and outpatient copay. We assigned each employer in a given calendar period to a propensity score quartile.
We then identified for inclusion all members age 12 to 64 with diabetes. We classified into these calendar period-quartiles all HDHP group diabetes patients with at least one year of continuous enrollment before and two years after the index date. We used member-level propensity score matching on age, gender, race/ethnicity, neighborhood poverty and education, US region, Adjusted Clinical Groups score, and calendar index month. Based on evidence that propensity score matching on the functional form of the baseline outcome trend closely approximates randomized controlled trial results, 5 we also matched on baseline quarterly rates of high-priority primary care and specialist visits, emergency department visits, and hospitalizations, as well as out-of-pocket expenditures. To create the final cohort, we performed this match, within the calendar period employer quartiles, on members who transitioned to a HDHP between January 2004 to January 2011 (allowing a 2 year follow-up ending in December 2012 at the latest) to contemporaneous control members using 1:1 caliper matching without replacement. We used a caliper width equal to 0.2 of the logit of the pooled standard deviation of the propensity score, which has been found to eliminate the majority of bias due to measured confounding variables. 4, 6 
C. Outcomes Measures
High-and low-priority outpatient visits
We applied a taxonomy developed by Fenton and colleagues 33 to characterize each office visit among diabetes patients as "high-priority" or "low-priority" based on the primary diagnosis, with high-priority conditions being considered those more likely to benefit from medical care than low-priority diagnoses. 33 The classification system was originally derived from the Oregon Prioritized Health Services List, which included an evidence-based ranking of over 700 diagnosis and treatment combinations according to the expected morbidity or mortality benefits of medical care. 33, 34 In our baseline sample, the five most common low-priority diagnoses were acute upper respiratory infections, acute sinusitis, acute pharyngitis, allergic rhinitis, and cough, while the most common high-priority diagnoses were diabetes, hypertension, hyperlipidemia, coronary heart disease, and acute bronchitis.
Outpatient disease monitoring measures
Outpatient disease monitoring measures were captured based on Healthcare Effectiveness Data and Information Set specifications, including ≥1 or more annual: primary care visit; hemoglobin A1c, low-density lipoprotein cholesterol, and microalbumin test; and retinal eye examination. Codes used to capture these tests are listed in eTable 3.
Creation and validation of a measure of diabetes acute complications
Overview: We sought to create a measure of outpatient and emergency department visits indicating that a patient had experienced a diabetes complication that can arise when patients defer or skip necessary care. We defined these acute diabetes complications as symptoms or conditions that may be associated with inappropriately deferring recommended or urgently needed diabetes-related outpatient or emergency department care for up to 4 months and that require timely care by medical professionals. eFigure 1 displays the 5-step decision algorithm we used to operationalize this definition on claims-data-based diagnoses. Our general goal was to choose specific primary diagnoses with a high degree of face validity for being possibly related to deferral of appropriate care. Other important considerations were that complications by definition must require urgent or emergent care by a medical professional (i.e., they could not be treated at home) and that certain diagnoses have different meanings when coded in the outpatient or emergency department setting (e.g. "congestive heart failure" is more likely to represent an acute complication if coded as the primary diagnosis in the emergency department versus outpatient setting).
Candidate ICD-9 codes:
We developed an initial set of candidate ICD-9 codes using a published list of acute and long-term diabetes complications used to examine the economic impacts of diabetes. 7 We also included diagnoses from the Agency for Healthcare Research and Quality's claims-based Prevention Quality Indicators (http://www.qualityindicators.ahrq.gov/Modules/pqi_resources.aspx) diabetes complications measures which include a smaller number of acute and long-term diabetes complications. The two clinicians on our team (E.M.E and J.F.W.) added three diagnoses with a high degree of face validity for being potentially related to gaps in appropriate diabetes and diabetes-related care: hypoglycemia, influenza, and pneumonia.
Classification for inclusion in final measure:
The two clinicians on our team (an endocrinologist [E.M.E.] and a general internist/ urgent care physician [J.F.W.]) then independently applied the 5-step decision algorithm shown in eFigure 1 to each of the ICD-9 codes, separately classifying them as a potential acute complication when coded as the primary diagnosis in either the outpatient or emergency department setting. We excluded any diagnoses (the "No" branches as shown in eFigure 1) for which the answer to any of the 5 steps was uncertain or ambiguous, in order to prioritize specificity over a sensitivity. After each clinician classified the diagnoses independently, we selected for inclusion in the final measure only those ICD-9 codes where both clinicians agreed that the diagnosis represented a recent acute complication. We therefore ended up with a list of 64 outpatient and 89 emergency department acute diabetes complication ICD-9 codes (eTable 4).
Creation of acute diabetes complication visit measure:
We then captured the primary diagnosis coded by clinicians (using evaluation and management CPT codes and the associated first ICD-9 codes) at all outpatient or emergency department visits. We separately flagged outpatient and emergency department visits that had a primary diagnosis on the respective list shown in eTable 4. Because we did not want to count repeat visits for a single complication episode, we required an interval of 10 days after a first detected episode of a complication. For example, if a patient was diagnosed with cellulitis on day 1 then was seen for this again on days 3 and 7, we would only count this as one episode rather than three.
Validation of acute diabetes complication visit measure:
We validated two aspects of our acute diabetes complication measure: (1) the association of gaps in outpatient care (including prescription drug use) and emergency department care with subsequent acute complications and (2) the association of diabetes complication visits with subsequent hospitalizations. Our basic respective hypotheses were: (1) Because diabetes patients who are not diet controlled should have essentially all enrollment days "covered" by medication on hand, and/or should present with concerning symptoms within days (e.g. within 7 or fewer days), any gaps in care of 7 or more days would be associated with a higher risk of subsequent acute complication visits than periods when there were no gaps in care; and (2) Because our definition of complications comprised symptoms and conditions that require urgent or emergent medical attention, acute complications would be associated with an increased risk of subsequent hospitalizations.
Association of gaps in care with complications.
We first identified gaps in outpatient and emergency department care as any day when a diabetes patient, who had received at least a 1 month supply of a medication related to preventing or treating diabetes or its complications, subsequently had days without such medications or without an outpatient or emergency department visit. The classes of drugs we included as potentially related to preventing or treating diabetes or its complications, based on AHFS categories, were: antibacterial (AHFS: 0812), antifungal (0814), autonomic (12) , blood/coagulation (16, 20), cardiac (2404), lipid lowering (2406), antihypertensive (2408), vasodilator (2412), analgesics/antipyretics (2808), antidepressant (281604), antipsychotic (281608), ear/nose/throat (52), insulin (682008), oral antidiabetic (6820), and skin agents (84). Among patients who had at least one gap between 7 to 120 days long ("gap group," n=297,413 of 364,020), we then randomly selected a sample equal to half (n=182,010) of our overall pool of diabetes patients. We randomly selected one gap (i.e., range of dates with no diabetes-related care) to analyze for each of the randomly selected 182,010 patients. We propensity score matched (caliper; 1:1 ratio) each member in the "gap group" to the other half of the pool of patients based on date of diabetes diagnosis, date of first diabetes-related prescription, date of end of enrollment, age group, AHFS morbidity score, race/ethnicity, education, gender, poverty, and US region of residence. This left us with 158,916 "gap group" patients and their matched controls. Because the matched control patient would not necessarily have a "non-gap" period during the exact contemporaneous days that the "gap group" had gaps, we restricted the sample to the pairs where the patient with a gap had a matched control with an exact contemporaneous non-gap (n= 39,828 in both groups). We used logistic regression to estimate the odds of an acute complication on the day following a gap in care compared to the day following the contemporaneous period of the matched subject. eTable 5 shows the raw frequencies of acute complications following gaps and non-gaps, corresponding to an odds ratio of 7.5 (4.9, 11.5). (We also performed the same analysis, but regardless of whether the matched "potential non-gap" member had a contemporaneous "non-gap" or not, but ensuring enrollment during the period of interest, finding an odds ratio of 10.1 [7.3,14.1 
]).
Association of acute complications with subsequent hospitalizations. To confirm that the acute diabetes complications visits we selected were indeed high acuity, we used logistic regression to estimate the odds of hospitalization within 3 days after the complication visit compared all other visits. We performed this analysis separately for outpatient visit acute complications (compared with non-acute complication outpatient visits) and emergency department acute complications (compared with non-acute complication emergency department visits). eTable 6 shows raw frequencies, and the corresponding odds ratios were 4.10 (3.98, 4.23) and 3.02 (2.96, 3.08), respectively.
D. Covariates
To estimate comorbidity, we applied the Adjusted Clinical Group (ACG) algorithm to members' baseline period. The algorithm uses age, gender, and ICD-9-CM codes to calculate a morbidity score and the average of the reference population is 1.0. 8 Researchers have validated the index against premature mortality.
9
To derive proxy demographic measures, the data vendor linked members' most recent residential street addresses to their 2000 US Census block group. 10 Census-based measures of socioeconomic status have been validated 11, 12 and used in multiple studies to examine the impact of policy changes on disadvantaged populations. [13] [14] [15] We classified members as from predominantly white, black, or Hispanic neighborhoods if they lived in a census block group (geocoding) with at least 75% of members of the respective race/ethnicity. We then applied a superseding ethnicity assignment if members had an Asian or Hispanic surname, 16 and classified remaining members as from mixed race/ethnicity neighborhoods. This validated approach of combining surname analysis and census data has positive and negative predictive values of approximately 80 and 90 percent, respectively.
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E. Analysis
For the high priority primary care and specialist visit outcomes, we first fit interrupted-time-series models 18 in order to both visually display monthly trends and confirm that the study groups did not have differential baseline trends, a key assumption of difference-in-differences analysis. We used difference-in-differences analysis to examine changes in annual high-priority outpatient visits and disease monitoring measures. We applied generalized estimating equations 19, 20 models with a negative binomial distribution for outpatient visits and a binary distribution for disease monitoring measures, controlling for (as appropriate) age, gender, race/ethnicity, education level, poverty level, US region, ACG score, employer size, and index date. The term that estimated the HDHP effect was the interaction between study group (HDHP versus control) and study period (follow-up year versus baseline). We applied marginal effects methods 21 to estimate adjusted rates of measures and to estimate adjusted absolute and relative baseline-to-follow-up changes in the HDHP group versus the control group.
To examine study group differences in time to first outpatient and emergency department visit for acute complications, we used separate Cox proportional hazards regression models for the baseline and follow-up periods, adjusting for the same covariates as above. The term of interest from the regression models was a binary indicator of membership in the HDHP group. This term generated adjusted hazard ratios (aHR) of the HDHP group compared to the control group in the baseline or follow-up periods.
To analyze annual changes in complication visits and associated subsequent 7-day total costs, we applied aggregate-level segmented regression to adjusted cumulative rates. This involved first using generalized estimating equations 19, 20 with a Poisson distribution to model monthly visit rates and costs in both study groups, adjusting for the covariates above and accounting for clustering at the person level. 22 We then applied marginal effects methods 21 to calculate monthly rates in both groups that were fully adjusted for the preceding covariates. We generated cumulative monthly rates 23,24 from these adjusted monthly rates, and plotted the cumulative control and HDHP group rates before and after the index date. This approach allows visualization of changes in rare outcomes that gradually accrue over time and prediction of cumulative rates at a given follow-up time point based on the baseline trend in the monthly cumulative points. We modelled cumulative HDHP and control group trends using aggregate-level segmented regression, 18 adjusting standard errors for autocorrelation. The regression models included intercept, baseline trend, trend change, and quadratic trend change terms for the HDHP and control groups, and were included in final models using backwards elimination with a threshold of p<0.05. Using marginal effects methods, 21 we estimated absolute and relative changes in the HDHP group compared with the control group at the end of follow-up versus the end of baseline using the above segmented regression terms.
Using the same methods and outcomes, we conducted subgroup analyses stratified by low-and high-income and morbidity and examined HSA members and their matched pairs. We also assessed several other subgroups of interest including by other income cutoffs (residing in neighborhoods with under 10%, over 5%, and over 20% of households below the Federal poverty level), and residents of predominantly white and nonwhite race neighborhoods.
II. eResults A. Changes in Out-of-Pocket Exposure
The overall, low-morbidity, high-morbidity, high-income, low-income, and HSA diabetes HDHP groups experienced increases in mean out-of-pocket medical expenditures of 49.4% (40.3%,58.4%; absolute: $374.6), 56.8% (45.8%,67.8%; absolute: $292.0), 40.9% (31.5%,50.4%; absolute: $448.8), 48.4% (37.2%,59.6%; absolute: $361.8), 51.7% (38.6%,64.7%; absolute: $400.4), and 67.8% (47.9%,87.8%; absolute: $463.0), respectively, relative to controls in the year after transitioning to HDHPs (eTable 7). Out-of-pocket obligations for hemoglobin A1c, LDL-C, and microalbumin tests increased from a mean of $1.2-$1.4 at baseline among HDHP members to $2.2-$4.8 at follow-up (eTable 8). Primary care visit costs increased from $15.4 to $23.3-$26.8 from baseline to follow-up among HDHP members, while specialist visits averaged $23.3 at baseline and approximately $42 at follow-up.
B. Utilization and Disease Monitoring Measures
Interrupted time series analyses demonstrated no statistically significant baseline trend differences between the HDHP and control groups in high priority outpatient visits for all subgroups (implying validity of differencein-differences estimates; eTable 9 and eFigure 2) except primary care visits among low-morbidity members.
C. Health Outcome Measures
The overall HDHP diabetes cohort experienced a follow-up period delay in the time to first outpatient complication visit compared with controls (adjusted hazard ratio [aHR], 0.94; 95% CI, 0.88-0.99; eTable 10 and eFigure 3) that was not present at baseline (aHR, 1.01; 95% CI, 0.93 to 1.09). eTable 10 also lists all other aHRs from subgroups of interest. Total annual ED complication visits and complication episode expenditures increased by 8.0% (95% CI, 4.6%-16 11.4%) and 5.6% (95% CI, 3.8%-7.3%), respectively, in the overall HDHP group compared with the controls (eTable 11 and eFigure 3). Corresponding changes in these ED outcomes among HSA HDHP members were 15.5% (95% CI, 10.5% to 20.6%) and 29.6% (95% CI, 19.0% to 40.1%; eFigure 4 and eTable 11). eTable 11 also lists all other total annual ED complication visit and complication episode expenditure findings from subgroups of interest.
D. Other Subgroups and Sensitivity Analyses
In analyses of other subgroups of interest, HDHP impacts on high-priority visits (eTable 12) and disease monitoring measures (eTable 13) among key HDHP subgroups did not differ substantially from the overall cohort. Alternate cutoffs for the income group definitions were generally consistent with the hypothesis that HDHP groups with lower income experienced greater adverse outcomes (eTables 10 and 11; eFigure 5), and non-white neighborhood residents also experienced substantial increases in acute complication measures. Restricting to members age 18-64 yielded similar outpatient visit, disease monitoring, and time-to-visit results compared with the age 12-64 cohort, but increases on acute complication measures were generally more pronounced (eTable 14-17).
Analyses of the top 5 most common emergency department complication visits demonstrated effect estimates with similar directions as in the main analysis except among HSA-eligible HDHP members (the smallest subgroup), among whom we detected no statistically significant changes (eTable 18). Adjusted Clinical Groups (see manuscript) score of 3. 4 Living in neighborhoods with below poverty levels of less than 5%. 5 Living in neighborhoods with below poverty levels of 10% or greater. 6 Health Savings Accounts allow pre tax contributions from employers or members, funds that can be used to pay for qualified medical expenses. 7 Living in neighborhoods with below poverty levels of less than 10%. 8 Living in neighborhoods with below poverty levels of 5% or greater. 9 Living in neighborhoods with below poverty levels of 20% or greater. 10 Living in neighborhoods with at least 75% of residents having white race. 11 Living in neighborhoods with fewer than 75% or residents having white race. 1 All rates and changes estimated using the STATA margins and nlcom commands and adjusted for (as appropriate) age, gender, race/ethnicity, education level, poverty level, US region, ACG score, employer size, and index date. 2 Living in neighborhoods with below poverty levels of less than 10%. 3 Living in neighborhoods with below poverty levels of 5% or greater. 4 Living in neighborhoods with below poverty levels of 20% or greater. 5 Living in neighborhoods with at least 75% of residents having white race. 6 Living in neighborhoods with fewer than 75% or residents having white race. 
